An interventional study of DEPASSE Apllication in Current Major Depressive Disorder, sponsored by University Hospital, Montpellier. Terminated at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-09-30.
Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Other
Among 126 studies in Depressive Disorder, Major with a site in France — 28 open to participants now, 30 under way, 2 of them phase 3. Depressive Disorder, Major · France.
Among the 126 studies in Depressive Disorder, Major with a site in France, this one is the 93rd largest by enrollment of the 105 interventional ones, is one of 9 that started in 2017, is one of 49 with no phase, and was the 65th registered.
3,041 studies on the registry are indexed under Depressive Disorder, Major; 588 are open to participants now.
This study's enrollment of 38 is below the median of 79 across 2,530 interventional studies indexed under Depressive Disorder, Major.
Browse Depressive Disorder, Major studies →28 of the 126 studies in Depressive Disorder, Major with a site in France are open now, in 7 countries. Each count lists the studies.
Of the 410 Depressive Disorder, Major studies recruiting now, 92 (22%) set no upper age limit and 292 (71%) stop at 75 or younger; 54 take children under 18; 98 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →126 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 9 started in 2017.
Median enrollment 230 across the 105 interventional studies, 128 across the 21 observational. Of the 84 that completed or were terminated, 31 (37%) have results posted.
62 of 126 have an industry lead sponsor. The 10 most frequent:
University Hospital, Montpellier is the lead sponsor of 1,261 studies on the registry; 224 are open to participants now.
University Hospital, Montpellier has 8 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
7 of the studies in Depressive Disorder, Major with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07316803Centre hospitalier de Ville-Evrard, FranceGroup Intervention for Romantic Relationships in Young Adults With Severe Mental Illness | 2026-11-30 |
| NCT06234176Centre Hospitalier EsquirolImpact of Psychomotor Therapy on the Quality of Life in Depression | 2027-02 |
| NCT06601140EmobotEvaluation of the Concordance Between Measures Obtained by a Medical Device for Emotional Monitoring (EMOCARE) and the Patient Health Questionnaire (PHQ-9) Score in Patients With Mild to Severe Depressive Episode | 2027-02-04 |
| NCT06732284Centre Hospitalier Universitaire de NīmesStudy of Sleep Inertia in Major Depressive Disorder by the Psychomotor Vigilance Task | 2027-03 |
Among the 126 studies in Depressive Disorder, Major with a site in France, from their registry updates:
Depression is a frequent disease and a serious public health problem, of which suicide is the most severe complication. Its treatment is based on the introduction of antidepressant which not only proposes a significant delay in the relief of symptoms but also by the phenomenon of lifting of inhibition can increase the suicidal risk during the initiation phase. Therefore there is a major interest in proposing a monitoring of these dark and suicidal ideas, immediately after the implementation of such treatment as well as other symptoms of depression. Thus, the aim of this study is to identify the mechanisms underlying this increase in dark and suicidal ideas in this context.
The study propose to assess, with an ecological momentary assessment method, the evolution of black ideas over 30 days following the introduction or switch of an oral antidepressants.
103 patients will be recruited suffering from a current major depressive disorder in the Montpellier University Hospital.
Each patient will attend a total of 3 scheduled visits, which will be completed over a period of 1 month (inclusion, between 10-15 days, 1 month. During this month, the patient will have to complete daily assesments throught a smartphone application "Depasse".
This Servier application allows the daily monitoring of symptoms allowing a regular evaluation, in the form of smileys simulating a Likert type scale evaluation of 1 to 5.
10 parameters are evaluated: moral, black thoughts, sleep, stress, concentration, social activities, energy, pleasure, motivation and libido. Note that when the patient expresses dark thoughts, he is then asked if he wants to hurt himself. If he answers yes, he is then asked to contact an emergency service.
One of its originalities is the addition of positive psychology approaches with a positive reinforcement of this evaluation through reward by a smiley in a smiley box and obtaining a "pleasant" image for motivation and incentive.
There is the possibility to have the graphical follow-up of the various parameters and to send them by mail to his treating psychiatrist.
Advice adapted to the mood of the day is provided taking into account the "dysfunctional" parameters.
Similarly, the emergency buoy tool provides access to emergency numbers and directs the patient to seek care.
Intelligence of the weight and the treatments established. The app also has a notification setting to remind the patient to evaluate themselves daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients performed the same evaluation : ecological momentary assesement throught smartphone and 3 sheduled visits. All patients are depressed patients.
Other: DEPASSE Apllication
Application DEPASSE in depressed patients. This application was developed by the laboratory SERVIER, by a scientific committee of psychologists and psychiatrists: Pr. Courtet, Dr Rimlinger and Pr. Swendsen. Depasse is available for all on the App store and on Googleplay. This application has several interests: \- The first is the daily monitoring of the symptoms allowing a regular evaluation throught smileys simulating a scale from 1 to 5. The 10 parameters evaluated are: mood, dark ideas, sleep, stress, concentration, social activities, energy, pleasure, motivation and libido. There is the possibility to generate a graph representing the evolution of these parameters. Tips adapted to the actual mood are provided related to the "dysfunctional" parameters.
Values of dark ideas assessed with a Likert type scale [1;5]
Evolution of dark ideas over 30 days. Throught the DEPASSE smartphone application, the patient assess the actual frequency of dark ideas from a Likert type scale of 1 (= not at all) to 5 (= often)
Time frame: 1 month
Values of the actual mood assessed with a Lickert type scale [1;5]
Evolution of the mood over 30 days. Throught the DEPASSE smartphone application, the patient evaluates whether he/she is in a good mood from 1 (= not at all) to 5 (= absolutely)
Time frame: 1 month
Values of the actual motivation assessed with a Lickert type scale [1;5]
Evolution of the mood over 30 days. Throught the DEPASSE smartphone application, the patient evaluates his/her motivation from 1 (= not at all) to 5 (= absolutely)
Time frame: 1 month
Values of the ability to feel pleasure as usual assessed with a Lickert type scale [1;5]
Evolution of the mood over 30 days. Throught the DEPASSE smartphone application, the patient evaluates his/her the ability to feel pleasure as usual from 1 (= not at all) to 5 (= absolutely)
Time frame: 1 month
Values of the energy assessed with a Lickert type scale [1;5]
Evolution of the mood over 30 days. Throught the DEPASSE smartphone application, the patient evaluates whether he/she feels energetic from 1 (= not at all) to 5 (= absolutely)
Time frame: 1 month
Values of the social activities assessed with a Lickert type scale [1;5]
Evolution of the mood over 30 days. Throught the DEPASSE smartphone application, the patient assesses whether he or she is involved in social activities from 1 (= not at all) to 5 (= absolutely)
Time frame: 1 month
Values of the concentration assessed with a Lickert type scale [1;5]
Evolution of the mood over 30 days. Throught the DEPASSE smartphone application, the patient assesses his/her ability to concentrate as usual from 1 (= not at all) to 5 (= absolutely)
Time frame: 1 month
Values of the stress assessed with a Lickert type scale [1;5]
Evolution of the mood over 30 days. Throught the DEPASSE smartphone application, the patient assesses whether he feels relaxed from 1 (= not at all) to 5 (= absolutely)
Time frame: 1 month
Values of the libido assessed with a Lickert type scale [1;5]
Evolution of the mood over 30 days. Throught the DEPASSE smartphone application, if the patient has the same libido as usual from 1 (= not at all) to 5 (= absolutely)
Time frame: 1 month
Values of sleep assessed with a Lickert type scale [1;5]
Evolution of the mood over 30 days. Throught the DEPASSE smartphone application, if the patient sleep well from 1 (= not at all) to 5 (= absolutely)
Time frame: 1 month
Score at the Montgomery-Åsberg Depression Rating Scale (MADRS)
Link between the self evaluation of the patient and the evaluation conducted by the psychiatrist
Time frame: 1 month
Score at the Columbia Suicide Severity Rating Scale (CSSRS)
Link between the self evaluation of the patient and the evaluation conducted by the psychiatrist
Time frame: 1 month
Number of emergency room visits
Link between the evolution of dark ideas over 1 month and the number of emergency room visits
Time frame: 1 month
Number of hospitalizations
Link between the evolution of dark ideas over 1 month and the number hospitalizations
Time frame: 1 month
Satisfaction score on the Lickert type scale [1;5]
Assessment of the patient satisfaction regarding the utilization of DEPASSE, from 1 (= not at all) to 5 (= absolutely)
Time frame: 1 month
Plan to share: Undecided — NC
No publications or documents are linked to this record.
Ran from Nov 2017 to primary completion in Dec 2018, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier →